Acknowledgement
Supported by : Il-dong Pharmaceutical Company, Korean Pediatric Society
References
- Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med 2007; 28:23-42 https://doi.org/10.1016/j.ccm.2006.11.010
- Dai ZK, Tan MS, Chai CY, Yeh JL, Chou SH, Chiu CC, et al. Upregulation of endothelial nitric oxide synthase and endothelin-1 in pulmonary hypertension secondary to heart failure in aorta-banded rats. Pediatr Pulmonol 2004;37:249- 56 https://doi.org/10.1002/ppul.10413
- Kim H, Yung GL, Marsh JJ, Konopka RG, Pedersen CA, Chiles PG, et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000;15:640-8
- Chen L, He H, Fernandez Mondejar E, Freden F, Wiklund P, Alving K, et al. Endothelin-1 and nitric oxide synthase in short rebound reaction to short exposure to inhaled nitric oxide. Am J Physiol Heart Circ Physiol 2001;281:H124-31 https://doi.org/10.1152/ajpheart.2001.281.1.H124
- Park HK, Park SJ, Kim CS, Paek YW, Lee JU, Lee WJ. Enhanced gene expression of renin-angiotensin system, TGF-beta1, endothelin-1 and nitric oxide synthase in right-ventricular hypertrophy. Pharmacol Res 2001;43:265- 73 https://doi.org/10.1006/phrs.2000.0777
- Kogler H, Hartmann O, Leineweber K, Nguyen van P, Schott P, Brodde OE, et al. Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat. Circ Res 2003;93:230-7 https://doi.org/10.1161/01.RES.0000085042.89656.C7
- Sastry BK. Pharmacologic treatment for pulmonary arterial hypertension. Curr Opin Cardiol 2006;21:561-8
- Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:39-45 https://doi.org/10.1164/rccm.200302-282OC
- Lee SH, Channick RN. Endothelin antagonism in pulmonary arterial hypertension. Semin Respir Crit Care Med 2005;26: 402-8 https://doi.org/10.1055/s-2005-916155
- Morice AH, Mulrennan S, Clark A. Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension. Eur Respir J 2005;26:180-1 https://doi.org/10.1183/09031936.05.00030405
- Dai ZK, Tan MS, Chai CY, Chou SH, Lin PC, Yeh JL, et al. Effects of sildenafil on pulmonary hypertension and levels of ET-1, eNOS, and cGMP in aorta-banded rats. Exp Biol Med (Maywood) 2006;231:942-7
- Dupuis J. Endothelin-receptor antagonists in pulmonary hypertension. Lancet 2001;358:1113-4 https://doi.org/10.1016/S0140-6736(01)06298-5
- Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5 https://doi.org/10.1038/332411a0
- Janakidevi K, Fisher MA, Del Vecchio PJ, Tiruppathi C, Figge J, Malik AB. Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol 1992;263:C1295-301 https://doi.org/10.1152/ajpcell.1992.263.6.C1295
- Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61: 227-37 https://doi.org/10.1016/j.cardiores.2003.11.026
- Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-65 https://doi.org/10.1161/01.CIR.0000102381.57477.50
- Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PA, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996;60:124- 37 https://doi.org/10.1016/S0009-9236(96)90127-7
- Todd L, Mullen M, Olley PM, Rabinovitch M. Pulmonary toxicity of monocrotaline differs at critical periods of lung development. Pediatr Res 1985;19:731-7
- Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993;73:887-97
- Prie S, Leung TK, Cernacek P, Ryan JW, Dupuis J. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6- dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 1997;282:1312-8
- Filep JG, Clozel M, Fournier A, Foldes-Filep E. Characterization of receptors mediating vascular responses to endothelin-1 in the conscious rat. Br J Pharmacol 1994;113:845-52
- Hill NS, Warburton RR, Pietras L, Klinger JR. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol 1997;83:1209- 15
- Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood) 2006;231:967-73
- Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, et al. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:34-8 https://doi.org/10.1164/rccm.200303-346OC
Cited by
- Effects of Bosentan Treatment on Angiotensin Converting Enzyme in Monocrotaline Induced Pulmonary Hypertension Rats vol.17, pp.1, 2011, https://doi.org/10.5646/jksh.2011.17.1.28